Treatment optimization: An outline for future success

Charles Williams Flexner, Ben Plumley, David H. Brown Ripin

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: In this issue of Current Opinion, the Guest Editors and their colleagues provide a comprehensive overview of current activities aimed at optimizing global HIV treatment. In this introduction, we outline current goals and approaches that will be described in more detail elsewhere in this issue. RECENT FINDINGS: Two recent conferences, the first and second Conference on Antiretroviral Drug Optimization (CADO), brought together experts from academia, governments, foundations, the pharmaceutical industry, and community activists to develop a global HIV-treatment research agenda for the coming decade focused on better therapies and how to make them accessible to a broader population of people living with HIV. Important recommendations included a focus on more efficient process chemistry for antiretroviral drugs, investigation of antiretroviral dose reduction as a possible optimization strategy, recognition of the increasing importance of concurrent infections and comorbidities especially tuberculosis and aging-related diseases, and identifying a highly effective and affordable nontoxic, once-daily fixed-dose combination regimen for first-line treatment. SUMMARY: HIV treatment optimization is a process intended to enhance the long-term efficacy, adherence, tolerability, safety, convenience, and affordability of combination ART. The ultimate goal of this process is to expand access to well tolerated and effective lifetime treatment to all those in need.

Original languageEnglish (US)
Pages (from-to)523-527
Number of pages5
JournalCurrent Opinion in HIV and AIDS
Volume8
Issue number6
DOIs
StatePublished - Nov 2013

Fingerprint

HIV
Drug Industry
Pharmaceutical Preparations
Comorbidity
Tuberculosis
Safety
Infection
Research
Population
Therapeutics

Keywords

  • antiretroviral therapy
  • Conference on Antiretroviral Drug Optimization
  • fixed-dose combinations
  • regimen simplification
  • universal access

ASJC Scopus subject areas

  • Hematology
  • Oncology(nursing)
  • Immunology
  • Infectious Diseases
  • Virology
  • Oncology

Cite this

Treatment optimization : An outline for future success. / Flexner, Charles Williams; Plumley, Ben; Brown Ripin, David H.

In: Current Opinion in HIV and AIDS, Vol. 8, No. 6, 11.2013, p. 523-527.

Research output: Contribution to journalArticle

Flexner, Charles Williams ; Plumley, Ben ; Brown Ripin, David H. / Treatment optimization : An outline for future success. In: Current Opinion in HIV and AIDS. 2013 ; Vol. 8, No. 6. pp. 523-527.
@article{e4923432bc6b4075a43dd4048f451404,
title = "Treatment optimization: An outline for future success",
abstract = "PURPOSE OF REVIEW: In this issue of Current Opinion, the Guest Editors and their colleagues provide a comprehensive overview of current activities aimed at optimizing global HIV treatment. In this introduction, we outline current goals and approaches that will be described in more detail elsewhere in this issue. RECENT FINDINGS: Two recent conferences, the first and second Conference on Antiretroviral Drug Optimization (CADO), brought together experts from academia, governments, foundations, the pharmaceutical industry, and community activists to develop a global HIV-treatment research agenda for the coming decade focused on better therapies and how to make them accessible to a broader population of people living with HIV. Important recommendations included a focus on more efficient process chemistry for antiretroviral drugs, investigation of antiretroviral dose reduction as a possible optimization strategy, recognition of the increasing importance of concurrent infections and comorbidities especially tuberculosis and aging-related diseases, and identifying a highly effective and affordable nontoxic, once-daily fixed-dose combination regimen for first-line treatment. SUMMARY: HIV treatment optimization is a process intended to enhance the long-term efficacy, adherence, tolerability, safety, convenience, and affordability of combination ART. The ultimate goal of this process is to expand access to well tolerated and effective lifetime treatment to all those in need.",
keywords = "antiretroviral therapy, Conference on Antiretroviral Drug Optimization, fixed-dose combinations, regimen simplification, universal access",
author = "Flexner, {Charles Williams} and Ben Plumley and {Brown Ripin}, {David H.}",
year = "2013",
month = "11",
doi = "10.1097/COH.0000000000000003",
language = "English (US)",
volume = "8",
pages = "523--527",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Treatment optimization

T2 - An outline for future success

AU - Flexner, Charles Williams

AU - Plumley, Ben

AU - Brown Ripin, David H.

PY - 2013/11

Y1 - 2013/11

N2 - PURPOSE OF REVIEW: In this issue of Current Opinion, the Guest Editors and their colleagues provide a comprehensive overview of current activities aimed at optimizing global HIV treatment. In this introduction, we outline current goals and approaches that will be described in more detail elsewhere in this issue. RECENT FINDINGS: Two recent conferences, the first and second Conference on Antiretroviral Drug Optimization (CADO), brought together experts from academia, governments, foundations, the pharmaceutical industry, and community activists to develop a global HIV-treatment research agenda for the coming decade focused on better therapies and how to make them accessible to a broader population of people living with HIV. Important recommendations included a focus on more efficient process chemistry for antiretroviral drugs, investigation of antiretroviral dose reduction as a possible optimization strategy, recognition of the increasing importance of concurrent infections and comorbidities especially tuberculosis and aging-related diseases, and identifying a highly effective and affordable nontoxic, once-daily fixed-dose combination regimen for first-line treatment. SUMMARY: HIV treatment optimization is a process intended to enhance the long-term efficacy, adherence, tolerability, safety, convenience, and affordability of combination ART. The ultimate goal of this process is to expand access to well tolerated and effective lifetime treatment to all those in need.

AB - PURPOSE OF REVIEW: In this issue of Current Opinion, the Guest Editors and their colleagues provide a comprehensive overview of current activities aimed at optimizing global HIV treatment. In this introduction, we outline current goals and approaches that will be described in more detail elsewhere in this issue. RECENT FINDINGS: Two recent conferences, the first and second Conference on Antiretroviral Drug Optimization (CADO), brought together experts from academia, governments, foundations, the pharmaceutical industry, and community activists to develop a global HIV-treatment research agenda for the coming decade focused on better therapies and how to make them accessible to a broader population of people living with HIV. Important recommendations included a focus on more efficient process chemistry for antiretroviral drugs, investigation of antiretroviral dose reduction as a possible optimization strategy, recognition of the increasing importance of concurrent infections and comorbidities especially tuberculosis and aging-related diseases, and identifying a highly effective and affordable nontoxic, once-daily fixed-dose combination regimen for first-line treatment. SUMMARY: HIV treatment optimization is a process intended to enhance the long-term efficacy, adherence, tolerability, safety, convenience, and affordability of combination ART. The ultimate goal of this process is to expand access to well tolerated and effective lifetime treatment to all those in need.

KW - antiretroviral therapy

KW - Conference on Antiretroviral Drug Optimization

KW - fixed-dose combinations

KW - regimen simplification

KW - universal access

UR - http://www.scopus.com/inward/record.url?scp=84886101679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886101679&partnerID=8YFLogxK

U2 - 10.1097/COH.0000000000000003

DO - 10.1097/COH.0000000000000003

M3 - Article

C2 - 24100878

AN - SCOPUS:84886101679

VL - 8

SP - 523

EP - 527

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 6

ER -